Your browser doesn't support javascript.
loading
A personalized approach to the management of VWD.
Phua, Chai W; Berntorp, Erik.
Affiliation
  • Phua CW; Division of Hematology/Oncology, London Health Sciences Centre, Department of Medicine, Western University, ON, Canada. Electronic address: chai.phua@lhsc.on.ca.
  • Berntorp E; Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden.
Transfus Apher Sci ; 58(5): 590-595, 2019 Oct.
Article in En | MEDLINE | ID: mdl-31466808
The goal of treating Von Willebrand Disease (VWD) is to replace deficient or dysfunctional Von Willebrand Factor (VWF) protein. However, the choice of treatment has to be considered carefully in view of patient factors and the unique properties of replacement products. Tailoring a treatment plan to an individual patient's bleeding challenge is an intricate process. This review describes personalization of treatment selection for desmopressin (DDAVP), VWF replacement concentrates, including the newly available recombinant VWF (rVWF) and prophylaxis as a treatment approach in VWD.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Von Willebrand Diseases / Von Willebrand Factor / Deamino Arginine Vasopressin / Precision Medicine / Hemorrhage Type of study: Prognostic_studies Limits: Humans Language: En Journal: Transfus Apher Sci Journal subject: HEMATOLOGIA Year: 2019 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Von Willebrand Diseases / Von Willebrand Factor / Deamino Arginine Vasopressin / Precision Medicine / Hemorrhage Type of study: Prognostic_studies Limits: Humans Language: En Journal: Transfus Apher Sci Journal subject: HEMATOLOGIA Year: 2019 Type: Article